An Industry In Transition
C&EN examines how the pharmaceutical industry, now on the defensive, is trying to win back the public's confidence and enhance productivity
Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Copyright © 2024 American Chemical Society
June 19, 2006 Cover
Volume 84, Issue 25
C&EN examines how the pharmaceutical industry, now on the defensive, is trying to win back the public's confidence and enhance productivity
Credit:
Pharmaceuticals
Triple Cascade
Asymmetric reaction constructs three new C-C bonds and four stereocenters
Pharma In Flux
Fundamental changes erupt across the industry as companies strive to improve drug efficacy and safety and R&D efficiency in the face of negative public opinion
-
Improving Efficiency
To eliminate R&D bottlenecks, drug companies are evaluating all phases of discovery and development and are using novel approaches to speed them up
-
Patient Activism
Researchers Are Admonished To Stay Focused
-
Effective Manufacturing
FDA Process Guidelines Encourage Efficient Plant Controls
ADVERTISEMENT
Science Concentrates
Regulatory Trends
Strong action on drug safety and pricing is more likely to come from states than from Congress or FDA
Business & Policy Concentrates
ADVERTISEMENT
EDITORIAL
REACTIONS FROM OUR READERS
- Platinum problems
- Safe designs
- Immigration debate
- Ethics and norms
- Battling the bugs
- Water vapor's effects
- Employment issues
- Say yes to solid waste
- Cold drinks get hot
